New RSV immunization approved by FDA. Why it’s ‘an important development in pediatric medicine’

This electron microscope image provided by the National Institutes of Health shows human respiratory syncytial virus (RSV) virions, colorized blue, and anti-RSV F protein/gold antibodies, colorized yellow, shedding from the surface of human lung cells. National Institute of Allergy and Infectious Diseases, NIH via AP

For many parents and babies, this past winter was a rough time as an early flu season combined with RSV (respiratory syncytial virus) and COVID-19 to create a “tripledemic” of infectious respiratory illnesses.

This coming winter could spell relief from infant RSV.

This week, the FDA approved a monoclonal antibody treatment to protect infants and young babies against RSV, which the American Academy of Pediatrics says results in the hospitalization of approximately 1 to 3% of children under 12 months of age every year.

Continue reading at Northeastern Global News